248 related articles for article (PubMed ID: 24830414)
1. Rescue of notch-1 signaling in antigen-specific CD8+ T cells overcomes tumor-induced T-cell suppression and enhances immunotherapy in cancer.
Sierra RA; Thevenot P; Raber PL; Cui Y; Parsons C; Ochoa AC; Trillo-Tinoco J; Del Valle L; Rodriguez PC
Cancer Immunol Res; 2014 Aug; 2(8):800-11. PubMed ID: 24830414
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk.
Thounaojam MC; Dudimah DF; Pellom ST; Uzhachenko RV; Carbone DP; Dikov MM; Shanker A
Oncotarget; 2015 Oct; 6(32):32439-55. PubMed ID: 26431276
[TBL] [Abstract][Full Text] [Related]
3. Notch controls generation and function of human effector CD8+ T cells.
Kuijk LM; Verstege MI; Rekers NV; Bruijns SC; Hooijberg E; Roep BO; de Gruijl TD; van Kooyk Y; Unger WW
Blood; 2013 Apr; 121(14):2638-46. PubMed ID: 23380742
[TBL] [Abstract][Full Text] [Related]
4. Notch signaling pathway dampens tumor-infiltrating CD8
Yu W; Wang Y; Guo P
Biomed Pharmacother; 2018 Jan; 97():535-542. PubMed ID: 29096354
[TBL] [Abstract][Full Text] [Related]
5. Notch2 signaling is required for potent antitumor immunity in vivo.
Sugimoto K; Maekawa Y; Kitamura A; Nishida J; Koyanagi A; Yagita H; Kojima H; Chiba S; Shimada M; Yasutomo K
J Immunol; 2010 May; 184(9):4673-8. PubMed ID: 20351182
[TBL] [Abstract][Full Text] [Related]
6. Notch signaling pathway suppresses CD8
Li S; Wang Z; Li XJ
Int Immunopharmacol; 2018 Oct; 63():129-136. PubMed ID: 30086535
[TBL] [Abstract][Full Text] [Related]
7. Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses.
Hossain F; Majumder S; Ucar DA; Rodriguez PC; Golde TE; Minter LM; Osborne BA; Miele L
Front Immunol; 2018; 9():1288. PubMed ID: 29915603
[TBL] [Abstract][Full Text] [Related]
8. Regulation of CD8
Tsukumo SI; Yasutomo K
Front Immunol; 2018; 9():101. PubMed ID: 29441071
[TBL] [Abstract][Full Text] [Related]
9. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.
Schouppe E; Mommer C; Movahedi K; Laoui D; Morias Y; Gysemans C; Luyckx A; De Baetselier P; Van Ginderachter JA
Eur J Immunol; 2013 Nov; 43(11):2930-42. PubMed ID: 23878002
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effect of lymphotactin and interferon gamma-inducible protein-10 transgene expression in T-cell localization and adoptive T-cell therapy of tumors.
Huang H; Xiang J
Int J Cancer; 2004 May; 109(6):817-25. PubMed ID: 15027114
[TBL] [Abstract][Full Text] [Related]
11. Involvement of Notch in activation and effector functions of γδ T cells.
Gogoi D; Dar AA; Chiplunkar SV
J Immunol; 2014 Mar; 192(5):2054-62. PubMed ID: 24489102
[TBL] [Abstract][Full Text] [Related]
12. T cells conditioned with MDSC show an increased anti-tumor activity after adoptive T cell based immunotherapy.
Raber PL; Sierra RA; Thevenot PT; Shuzhong Z; Wyczechowska DD; Kumai T; Celis E; Rodriguez PC
Oncotarget; 2016 Apr; 7(14):17565-78. PubMed ID: 27007050
[TBL] [Abstract][Full Text] [Related]
13. β-Adrenergic Signaling Impairs Antitumor CD8
Nissen MD; Sloan EK; Mattarollo SR
Cancer Immunol Res; 2018 Jan; 6(1):98-109. PubMed ID: 29146881
[TBL] [Abstract][Full Text] [Related]
14. Essential role of Notch signaling in effector memory CD8+ T cell-mediated airway hyperresponsiveness and inflammation.
Okamoto M; Takeda K; Joetham A; Ohnishi H; Matsuda H; Swasey CH; Swanson BJ; Yasutomo K; Dakhama A; Gelfand EW
J Exp Med; 2008 May; 205(5):1087-97. PubMed ID: 18426985
[TBL] [Abstract][Full Text] [Related]
15. Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy.
Kobold S; Grassmann S; Chaloupka M; Lampert C; Wenk S; Kraus F; Rapp M; Düwell P; Zeng Y; Schmollinger JC; Schnurr M; Endres S; Rothenfußer S
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26105028
[TBL] [Abstract][Full Text] [Related]
16. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
17. Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways.
Raber PL; Thevenot P; Sierra R; Wyczechowska D; Halle D; Ramirez ME; Ochoa AC; Fletcher M; Velasco C; Wilk A; Reiss K; Rodriguez PC
Int J Cancer; 2014 Jun; 134(12):2853-64. PubMed ID: 24259296
[TBL] [Abstract][Full Text] [Related]
18. Dynamic regulation of notch 1 and notch 2 surface expression during T cell development and activation revealed by novel monoclonal antibodies.
Fiorini E; Merck E; Wilson A; Ferrero I; Jiang W; Koch U; Auderset F; Laurenti E; Tacchini-Cottier F; Pierres M; Radtke F; Luther SA; Macdonald HR
J Immunol; 2009 Dec; 183(11):7212-22. PubMed ID: 19915064
[TBL] [Abstract][Full Text] [Related]
19. Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo.
Redmond WL; Gough MJ; Weinberg AD
Eur J Immunol; 2009 Aug; 39(8):2184-94. PubMed ID: 19672905
[TBL] [Abstract][Full Text] [Related]
20. Depletion of CD4(+)CD25(high) regulatory T cells from tumor infiltrating lymphocytes predominantly induces Th1 type immune response in vivo which inhibits tumor growth in adoptive immunotherapy.
Xu L; Xu W; Jiang Z; Zhang F; Chu Y; Xiong S
Cancer Biol Ther; 2009 Jan; 8(1):66-72. PubMed ID: 19029829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
